Stoneridge Investment Partners LLC Sells 8,480 Shares of Abbott Laboratories $ABT

Stoneridge Investment Partners LLC lowered its position in Abbott Laboratories (NYSE:ABT) by 41.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 12,214 shares of the healthcare product maker’s stock after selling 8,480 shares during the quarter. Abbott Laboratories makes up about 0.7% of Stoneridge Investment Partners LLC’s investment portfolio, making the stock its 27th largest holding. Stoneridge Investment Partners LLC’s holdings in Abbott Laboratories were worth $1,108,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the company. Brighton Jones LLC grew its holdings in Abbott Laboratories by 10.1% during the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after purchasing an additional 4,755 shares during the period. Sivia Capital Partners LLC raised its stake in Abbott Laboratories by 3.5% in the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock valued at $648,000 after buying an additional 162 shares during the period. United Bank lifted its position in shares of Abbott Laboratories by 7.4% in the second quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock valued at $3,945,000 after buying an additional 2,001 shares during the last quarter. Main Street Financial Solutions LLC boosted its stake in shares of Abbott Laboratories by 13.6% during the 2nd quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker’s stock worth $1,618,000 after acquiring an additional 1,428 shares during the period. Finally, Canada Pension Plan Investment Board boosted its stake in shares of Abbott Laboratories by 25.6% during the 2nd quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker’s stock worth $195,267,000 after acquiring an additional 292,547 shares during the period. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms recently weighed in on ABT. Royal Bank Of Canada restated an “outperform” rating and issued a $130.00 price target on shares of Abbott Laboratories in a research note on Friday, July 17th. JPMorgan Chase & Co. increased their price objective on shares of Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a research report on Friday, July 17th. Piper Sandler reiterated an “overweight” rating and issued a $118.00 price target (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. Wells Fargo & Company raised their price objective on shares of Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. Finally, TD Cowen upped their target price on Abbott Laboratories from $115.00 to $135.00 and gave the company a “buy” rating in a research report on Tuesday. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $119.50.

Abbott Laboratories Stock Performance

Shares of Abbott Laboratories stock opened at $114.11 on Thursday. The company’s 50 day moving average price is $101.66 and its two-hundred day moving average price is $100.13. The firm has a market capitalization of $197.45 billion, a P/E ratio of 36.93, a P/E/G ratio of 2.25 and a beta of 0.59. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $137.49. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company had revenue of $12.59 billion during the quarter, compared to analysts’ expectations of $12.52 billion. During the same period in the prior year, the company earned $1.26 EPS. Abbott Laboratories’s revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, equities analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend was Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 81.55%.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The FDA authorized Abbott’s Libre Duo 10 Day, the first U.S. wearable designed to continuously monitor both glucose and ketone levels. The device is intended to help detect rising ketones associated with diabetic ketoacidosis and integrates with Abbott’s Libre app, digital-health ecosystem and compatible automated insulin-delivery systems. The approval strengthens Abbott’s continuous glucose-monitoring franchise and could expand its addressable market. Reuters FDA authorization article
• Positive Sentiment: TD Cowen raised its price target for ABT from $115 to $135 and maintained a “buy” rating, implying approximately 18% upside from the referenced $114.11 level. The target increase reflects confidence in Abbott’s growth prospects and valuation relative to peers. Benzinga analyst price target report
• Neutral Sentiment: Industry forecasts identify Abbott as a participant in expanding atrial-fibrillation treatment and device markets, particularly pulsed-field ablation, mapping catheters and left-atrial-appendage closure. These reports point to long-term opportunity but do not provide new Abbott-specific financial guidance. Atrial fibrillation treatment devices market report
• Negative Sentiment: Abbott agreed to pay $670 million to settle claims that its specialized premature-infant formula contributed to necrotizing enterocolitis. The settlement removes some litigation uncertainty but highlights continuing legal and financial risks. Abbott formula claims settlement article

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.